Search
for
Sort by
Research 181–210 of 536
- 046 Analysing the mechanistic basis of Ritlecitinib’s therapeutic effects in Alopecia Areata
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
- Treatment of frontal fibrosing alopecia: literature review 2020-2025
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- European expert consensus statement on the systemic treatment of alopecia areata
- JAK inhibitors in dermatology: The promise of a new drug class
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Under Development JAK Inhibitors for Dermatologic Diseases
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 917 Frontal fibrosing alopecia scalp profiling links Th1/Th2 and JAK3 activation with fibrosis and loss of follicular stem cells
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
- 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects